Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 3/20 | 0.40 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KLK1 | P06870 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130351 | 0.90 | TP53 (0.48) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5131334 | 0.90 | NPC1 (0.44) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5121951 | 0.89 | RAB9A (0.46) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5118770 | 0.89 | RAB9A (0.45) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5240614 | 0.89 | RAB9A (0.45) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5117937 | 0.88 | HPGD (0.45) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5123458 | 0.88 | RAB9A (0.44) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5130154 | 0.87 | NPC1 (0.46) | NPC1RAB9AHPGDKDM4EALDH1A1 | |
| SCHEMBL5127204 | 0.85 | HDAC1 (0.45) | NPC1RAB9AHPGDHDAC1LMNA | |
| SCHEMBL5203922 | 0.83 | NPC1 (0.41) | NPC1RAB9AHPGDHDAC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | claimed |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2023-03-30 | — | — | US | disclosed |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE (IT) | 2008-09-11 | — | — | US | disclosed |
| EP-1768955-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885HPGD 1305/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885HPGD 1305/4885 |
| US-20080221157-A1 | Amide Derivatives as Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC4 | NPC1 881/4885RAB9A 2246/4885HPGD 475/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | NPC1 2251/4885RAB9A 3597/4885HPGD 1305/4885 |
| US-20230094176-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC2, HDAC1 | NPC1 2295/4885RAB9A 3925/4885HPGD 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.